New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line RRMM October 1, 2026
VERSATILE-002 Ph 2 Results of PDS0101 + pembrolizumab in HPV16+ve Recurrent and/or Metastatic (R/M) Head & Neck Cancer published in JAMA Oncology October 1, 2026
Final OS results from randomized Ph 2 OVATION 2 Study of IMNN-001 in IL advanced ovarian cancer October 1, 2026
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line RRMM October 1, 2026
New Analyses Reinforcing Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC Announced September 22, 2026
Lunsumio-based regimen significantly improves PFS in follicular lymphoma in Ph 3 CELESTIMO study September 22, 2026
Complete Full Cohort Ph 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent NSCLC Announced September 22, 2026
GX-BP1 Suppresses Tumor Regrowth despite Osimertinib and Dato-DXd Combination and Achieves 6/6 Complete Responses in Triple Combination September 22, 2026
Updated Data from Ph 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of BH-30643 in EGFR C797S-Positive NSCLC Presented September 22, 2026
Gotistobart Nearly Doubled Median OS versus SOC Chemo in Previously Treated Squamous NSCLC Patients September 16, 2026
Zipalertinib + chemo Demonstrates 6-Month Median PFS Benefit in REZILIENT3 Ph 3 Trial in 1L EGFR Exon 20 Insertion Mutation NSCLC September 16, 2026
FAILED TRIAL: SERENA-4 trial of Etcamah + palbociclib did not meet primary objective of statistically significant PFS improvement September 16, 2026
Complete Full Cohort Ph 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent NSCLC Announced September 16, 2026
Results from Ph 3 Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO September 16, 2026
Positive results announced from registrational Ph 1/2 ARROS-1 trial of Jideytro (zidesamtinib) in patients with advanced or metastatic TKI-naive ROS1-positive NSCLC September 16, 2026
Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed SCLC in China September 16, 2026
RYBREVANT® (amivantamab-vmjw) + chemo delivers long median OS in EGFR exon 20 insertion mutation-positive NSCLC September 16, 2026
Ph 3 data for Tam-Peli shows significantly improved OS in Chinese patient population with relapsed SCLC September 16, 2026
Tagrisso demonstrated eight-year survival in early-stage EGFR-mutated lung cancer in ADAURA Ph 3 trial September 16, 2026
Enhertu demonstrated a median PFS of 14.3 months IN 1L HER2-mutant advanced NSCLC in DESTINY-Lung04 Ph 3 trial September 16, 2026
INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Ph 2 HNSCC Study September 9, 2026
